Verastem - Turnaroundspekulation 2016

Schade, hab die Kurse unter 1.10$ verpasst, aber einen Alarm gesetzt falls es nochmal runter gehen sollte.

https://www.fool.com/investing/2020/08/10/...riefly-this-morning.aspx

 

Dann solltest du heute noch einsteigen.


Verastem Oncology Announces Investor Conference Call to Discuss Updated Clinical Data in Low-Grade Serous Ovarian Cancer from Phase 1/2 FRAME Study


-New Results Evaluating Combination of VS-6766 and Defactinib to be Presented at the 2nd Annual RAS-Targeted Drug Development Summit

-Management to Host Investor Conference Call and Webcast on Wednesday, September 16 at 8:00 AM ET


https://finance.yahoo.com/news/...-investor-conference-110000045.html  

Verastem Oncology Announces Presentation of Updated Phase 1/2 FRAME Study Data at the 2nd Annual RAS-Targeted Drug Development Summit


-Preliminary Data on VS-6766 and Defactinib Combination Continues to Show Encouraging Response Rates, Durability and a Favorable Safety Profile in KRAS Mutant Low-Grade Serous Ovarian Cancer in Investigator-Initiated Trial

-New Preclinical Data Demonstrating Synergy and Tumor Regression with G12C Inhibitors in Combination with VS-6766 and FAK Inhibitor In Vitro and In Vivo Also Presented


https://finance.yahoo.com/news/...presentation-updated-110000934.html  

https://old.nasdaq.com/de/symbol/vstm/real-time
 

http://ih.advfn.com/...p;width=800&vol=1&height=400&Vol=1  

VS-6766 Daten

https://investor.verastem.com/news-releases/...lished-lancet-oncology

 

Zurück auf Los.  

Zahlen für Q3/20

• Umsatz 79 Mio. $
  
  • 70 Mio. $ aus dem  COPIKTRA Verkauf
    
• Gewinn 13 Mio. $
  
• Cash 206 Mio. $
  
• MK 244 Mio. $
  

"Strategic Sale of COPIKTRA® (duvelisib) Provides Cash Runway Until at Least 2024"

https://investor.verastem.com/news-releases/...2020-financial-results

 

http://ih.advfn.com/...p;width=800&vol=1&height=400&Vol=1  

https://www.marketwatch.com/investing/stock/vstm  

https://www.marketwatch.com/investing/stock/vstm  

Verastem Oncology Initiates Phase 2 Registration-Directed Trial of VS-6766 and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer

Previous Data from Investigator-Initiated Phase 1/2 Trial Show Encouraging Response Rates, Durability and a Favorable Safety Profile

Phase 2 Adaptive Trial Design to Evaluate VS-6766 Alone and in Combination with Defactinib

Verastem to Seek FDA Accelerated Approval, Pending Trial Outcome

https://investor.verastem.com/news-releases/...tration-directed-trial  

BARBERICH TIMOTHY J
Shares: 50.000
Price: $2.17
Amount: $108,500
File date: 07.12.20

http://insiderbuyingselling.com/?t=VSTM  

Annual Changes to the Nasdaq Biotechnology Index

https://www.nasdaq.com/press-release/...omltfnd5Ydzg9ZvR-2rtzaHfdb16k  

jetzt sind wir leider schon gut  10% im Minus vom letzten Hoch , schade. Sah richtig gut , immer stetig nach oben. Meine ihr , es geht jetzt noch weiter runter !  

Phase 2 Registration-Directed Trial of VS-6766 and Defactinib in Previously Treated KRAS Mutant Non-Small Cell Lung Cancer

Phase 2 Adaptive Trial Design to Evaluate VS-6766 Alone and in Combination with Defactinib With a Focus on KRAS-G12V Mutations

Trial Designed to Address Significant Unmet Medical Need in These Treatment-Resistant Tumors

Verastem Oncology to Seek FDA Accelerated Approval, Pending Trial Outcome

https://finance.yahoo.com/news/...gy-initiates-phase-2-120000499.html  

Premarket mit verdammt niedrigen Volumen.  

CMO geht nach nur 2 Wochen

Das wirft natürlich Fragen auf...

https://www.fiercebiotech.com/biotech/...weeks-into-job-its-cmo-quits

 

 

die letzten Tage.
Baker Bros. haben sich mit 10,144,039 shares eingedeckt.

https://fintel.io/so/us/vstm  

CHMP recommends five new drugs, gives advice on Celltrion COVID antibody

... European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) on Friday issued positive opinions for five new medicines and six extensions of therapeutic indications following its meeting earlier this week.

The newly recommended medicines include Verastem’s Copiktra (duvelisib) to treat relapsed or refractory chronic lymphocytic leukemia and refractory follicular lymphoma and Janssen-Cilag’s multiple sclerosis treatment Ponvory (ponesimod). The committee also recommended two oral contraceptives with the same active substances, Gedeon Richter’s Drovelis (estetrol/drospirenone), Estetra SPRL’s Lydisilka (estetrol/drospirenone), and Diurnal Europe BV’s hybrid medicine Efmody (hydrocortisone) for patients 12 and older with congenital adrenal hyperplasia (CAH)....

https://www.raps.org/news-and-articles/...w-drugs-gives-advice-on-cel  

endlich loszugehen:

http://ih.advfn.com/...p;width=800&vol=1&height=400&Vol=1  

Untypisches hohes Volumen!

https://www.marketwatch.com/investing/stock/vstm?mod=over_search  

H.C. Wainwright analyst Sean Lee CFA maintained a Buy rating on Verastem (VSTM) today and set a price target of $4.00. The company’s shares closed last Wednesday at $2.80.

https://www.smarteranalyst.com/new-blurbs/...buy-from-h-c-wainwright/  

Haben ihren Anteil erhöht, halten aktuell nun 18.685.695 Mio. Shares!